Drugs / GO-203-2C
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01279603 | Jan 2011 → May 2013 | cancer | Genus Oncology, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02658396 | ? → May 2019 | plasma cell myeloma | Dana-Farber Cancer Institute | Withdrawn | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02204085 | Sep 2014 → Sep 2025 | acute myeloid leukemia | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GO-203-2C | “This research study is studying a targeted therapy known as GO-203-2C as a possible treatment for with acute myeloid leukemia (AML) both alone and in combination with decitabine.” NCT02204085 ↗ |
| Action | Inhibit | “MUC1 Inhibitor” NCT02204085 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4297466 ↗ |
| Route | Intravenous | “administered as a single agent intravenously over 60 minutes.” NCT01279603 ↗ |
| Target | MUC1 | “binds to an oncoprotein (a cancer causing protein) called MUC1 (which is over-expressed in many cancers).” NCT01279603 ↗ |